Lunai Bioworks Inc. has officially filed a Form 25 with the Securities and Exchange Commission (SEC) to delist its common stock from the Nasdaq. This filing, dated November 2, 2026, indicates the company's intention to withdraw its securities from listing and registration under the Securities Exchange Act of 1934. The decision to delist reflects Lunai Bioworks' ongoing restructuring efforts as it navigates challenges within the pharmaceutical preparations sector.

The move to delist is significant for Lunai Bioworks, a company that has undergone multiple name changes in recent years, previously known as Renovaro Inc. and Enochian Biosciences Inc. This transformation highlights the company's strategic shifts in response to market conditions and competitive pressures. The pharmaceutical preparations industry, as defined by its Standard Industrial Classification (SIC) code 2834, is known for its intense competition and rapid innovation, making it crucial for companies to adapt swiftly.

According to the SEC filing (accession number 0001731122-26-001389), Lunai Bioworks has confirmed that it meets the requirements for filing this Form 25. The filing states, "Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange." This indicates that the company has adhered to the necessary regulations for this process.

This delisting may impact various stakeholders, including investors, employees, and partners. Investors may need to reassess their positions as Lunai Bioworks transitions away from public trading. Employees could face uncertainties regarding job security and future opportunities within the company. Additionally, partners and suppliers may need to evaluate their relationships with Lunai Bioworks in light of its new status.

As of now, the filing does not specify what steps Lunai Bioworks will take next following the delisting. The company may pursue alternative strategies to enhance its operations and financial health in the competitive pharmaceutical landscape. Investors and industry observers will be watching closely to see how Lunai Bioworks navigates this transition.